Polynovo Ltd (PNV) - Total Assets
Based on the latest financial reports, Polynovo Ltd (PNV) holds total assets worth AU$123.37 Million AUD (≈ $87.29 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Polynovo Ltd - Total Assets Trend (1999–2025)
This chart illustrates how Polynovo Ltd's total assets have evolved over time, based on quarterly financial data. Also see Polynovo Ltd stock valuation for the company's overall valuation and market capitalisation.
Polynovo Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Polynovo Ltd's total assets of AU$123.37 Million consist of 60.5% current assets and 39.5% non-current assets. Review PNV current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$6.91 Million | 26.3% |
| Accounts Receivable | AU$24.39 Million | 19.1% |
| Inventory | AU$14.49 Million | 11.4% |
| Property, Plant & Equipment | AU$38.22 Million | 30.0% |
| Intangible Assets | AU$661.00K | 0.5% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Polynovo Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Polynovo Ltd (PNV) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Polynovo Ltd's current assets represent 60.5% of total assets in 2025, a decrease from 78.7% in 1999.
- Cash Position: Cash and equivalents constituted 26.3% of total assets in 2025, down from 76.7% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 21.0% in 1999.
- Asset Diversification: The largest asset category is property, plant & equipment at 30.0% of total assets.
Polynovo Ltd Competitors by Total Assets
Key competitors of Polynovo Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161
|
China | CN¥5.19 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Ningbo David Medical Device Co Ltd
SHE:300314
|
China | CN¥1.47 Billion |
|
Beijing Succeeder Technology Inc
SHG:688338
|
China | CN¥1.78 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.57 Billion |
|
Profound Medical Corp
TO:PRN
|
Canada | CA$62.28 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
Polynovo Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.03 | 3.46 | 2.28 |
| Quick Ratio | 2.51 | 2.84 | 2.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$46.41 Million | AU$56.09 Million | AU$8.32 Million |
Polynovo Ltd - Advanced Valuation Insights
This section examines the relationship between Polynovo Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.39 |
| Latest Market Cap to Assets Ratio | 3.64 |
| Asset Growth Rate (YoY) | 17.2% |
| Total Assets | AU$127.41 Million |
| Market Capitalization | $464.37 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Polynovo Ltd's assets at a significant premium (3.64x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Polynovo Ltd's assets grew by 17.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Polynovo Ltd (1999–2025)
The table below shows the annual total assets of Polynovo Ltd from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$127.41 Million ≈ $90.15 Million |
+17.19% |
| 2024-06-30 | AU$108.72 Million ≈ $76.93 Million |
+17.38% |
| 2023-06-30 | AU$92.62 Million ≈ $65.54 Million |
+164.85% |
| 2022-06-30 | AU$34.97 Million ≈ $24.74 Million |
-8.78% |
| 2021-06-30 | AU$38.34 Million ≈ $27.13 Million |
+1.27% |
| 2020-06-30 | AU$37.86 Million ≈ $26.79 Million |
+34.11% |
| 2019-06-30 | AU$28.23 Million ≈ $19.97 Million |
-5.34% |
| 2018-06-30 | AU$29.82 Million ≈ $21.10 Million |
+147.36% |
| 2017-06-30 | AU$12.06 Million ≈ $8.53 Million |
-24.77% |
| 2016-06-30 | AU$16.02 Million ≈ $11.34 Million |
+97.21% |
| 2015-06-30 | AU$8.13 Million ≈ $5.75 Million |
-13.68% |
| 2014-06-30 | AU$9.41 Million ≈ $6.66 Million |
+9.22% |
| 2013-06-30 | AU$8.62 Million ≈ $6.10 Million |
-3.26% |
| 2012-06-30 | AU$8.91 Million ≈ $6.30 Million |
-24.32% |
| 2011-06-30 | AU$11.77 Million ≈ $8.33 Million |
-21.64% |
| 2010-06-30 | AU$15.02 Million ≈ $10.63 Million |
-13.11% |
| 2009-06-30 | AU$17.29 Million ≈ $12.23 Million |
+0.73% |
| 2008-06-30 | AU$17.16 Million ≈ $12.14 Million |
-22.05% |
| 2007-06-30 | AU$22.02 Million ≈ $15.58 Million |
-11.75% |
| 2006-06-30 | AU$24.95 Million ≈ $17.65 Million |
+33.51% |
| 2005-06-30 | AU$18.69 Million ≈ $13.22 Million |
+0.19% |
| 2004-06-30 | AU$18.65 Million ≈ $13.20 Million |
+149.53% |
| 2003-06-30 | AU$7.47 Million ≈ $5.29 Million |
-40.75% |
| 2002-06-30 | AU$12.61 Million ≈ $8.93 Million |
+74.65% |
| 2001-06-30 | AU$7.22 Million ≈ $5.11 Million |
-39.62% |
| 2000-06-30 | AU$11.96 Million ≈ $8.46 Million |
+69.01% |
| 1999-06-30 | AU$7.08 Million ≈ $5.01 Million |
-- |
About Polynovo Ltd
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for her… Read more